Hoffmann-La Roche Limited (Roche Canada) today announced that Health Canada has approved GAZYVA® (obinutuzumab) in combination with bendamustine followed by GAZYVA monotherapy for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a RITUXAN® (rituximab)-containing regimen.
Each year, an estimated 2,800 Canadians are diagnosed with follicular lymphoma, a slow-growing form of non-Hodgkin’s lymphoma. While chemotherapy and targeted treatments such as RITUXAN – the current standard of care – have improved survival rates for patients impacted by the disease, follicular lymphoma often recurs.
“Despite significant improvements in the treatment of follicular lymphoma including the addition of rituximab to primary chemotherapy and the use of rituximab maintenance, follicular lymphoma remains an incurable disease,” said Dr. John Kuruvilla, a hematologist at Princess Margaret Hospital and Associate Professor at the University of Toronto. “New treatment options are needed for Canadians dealing with relapsed or refractory follicular lymphomas. GAZYVA in combination with bendamustine represents an important new advance for patients who have follicular lymphoma that has relapsed after, or was refractory to a rituximab-based treatment regimen.”